How Good do Current LHRH Agonists Control Testosterone? Can this be Improved with Eligard®?

Huggins, 1941, Studies on prostatic cancer. I. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, Cancer Res, 1, 293

Byar, 1988, Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies, NCI Monogr, 7, 165

Schally, 1971, Hypothalamic FSH and LH-regulating hormone. Structure, physiology and clinical studies, Fertil Steril, 22, 703, 10.1016/S0015-0282(16)38580-6

1984, Leuprolide versus diethylstilbestrol for metastatic prostate cancer, N Engl J Med, 311, 1281, 10.1056/NEJM198411153112004

Gommersall, 2002, Luteinising hormone releasing hormone analogues in the treatment of prostate cancer, Expert Opin Pharmacother, 3, 1685, 10.1517/14656566.3.12.1685

Oefelein, 2003, Effective testosterone suppression for patients with prostate cancer: is there a best castration?, Urology, 62, 207, 10.1016/S0090-4295(03)00331-5

Oefelein, 2000, Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making, Urology, 56, 1021, 10.1016/S0090-4295(00)00793-7

Kaisary, 1991, Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma, Br J Urol, 67, 502, 10.1111/j.1464-410X.1991.tb15195.x

Rohl, 1992, Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer, Scand J Urol Nephrol, 26, 11, 10.3109/00365599209180389

Lin, 1994, The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer, Urology, 43, 834, 10.1016/0090-4295(94)90145-7

Vogelzang, 1995, Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group, Urology, 46, 220, 10.1016/S0090-4295(99)80197-6

Zlotta A, Debruyne F. Expert opinion on optimal testosterone control in Prostate Cancer. Eur Urol Suppl. 2005;(4):37–41.

Esquena, 2004, Failure of luteinising hormonal releasing hormonal agonist therapy to achieve castration. Does it exist?, Eur Urol Suppl, 3, 57, 10.1016/S1569-9056(04)90219-9

Morote J. In Press.

Oefelein, 2000, Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm, J Urol, 164, 726, 10.1016/S0022-5347(05)67290-4

Wechsel, 1996, Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer, Eur Urol, 30, 7, 10.1159/000474238

McLeod, 2001, A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer, Urology, 58, 756, 10.1016/S0090-4295(01)01342-5

Kawakami, 2002, J Urol, 167, 288

Bubley, 2001, Is the flare phenomenon clinically significant?, Urology, 58, 5, 10.1016/S0090-4295(01)01235-3

Sharifi, 2002, Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer, J Urol, 168, 1001, 10.1016/S0022-5347(05)64560-0

Sarosdy, 1999, Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every13 weeks to patients with advanced prostate cancer, BJU Int, 83, 801, 10.1046/j.1464-410x.1999.00028.x

Zinner, 2004, Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6mg and 10.8mg: results of a randomized open-label trial, Urology, 64, 1177, 10.1016/j.urology.2004.07.033

Fontana, 2003, 3-month formulation of goserelin acetate (Zoladex) in advanced prostate cancer: results from an Italian open multicentre trial, Urol Int, 70, 316, 10.1159/000070142

Khan, 1998, An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate, Urol Int, 60, 33, 10.1159/000030200

Jocham, 1998, Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results, Urol Int, 60, 18, 10.1159/000056547

Tombal B. Data on file.

Chu, 2002, A clinical study of 22.5mg LA-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer, J Urol, 168, 1199, 10.1016/S0022-5347(05)64625-3

Perez-Marreno, 2002, A six-month, open-label study assessing a new formulation of leuprolide 7.5mg for suppression of testosterone in patients with prostate cancer, Clin Ther, 24, 1902, 10.1016/S0149-2918(02)80087-X

Perez-Marreno, 2004, A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer, Expert Opin Pharmacother, 5, 447, 10.1517/14656566.5.2.447